Current Gastroenterology Reports

, Volume 14, Issue 4, pp 343–348 | Cite as

Fighting Fire with Fire: Is it Time to Use Probiotics to Manage Pathogenic Bacterial Diseases?

  • John Heineman
  • Sara Bubenik
  • Stephen McClave
  • Robert MartindaleEmail author
Nutrition and Obesity (S McClave, Section Editor)


Probiotics, when considered in clinical practice, have traditionally been used for prophylaxis; however, there is growing data suggesting treatment benefits in numerous disease states. In this review, we focus on probiotics as treatment for and prevention of several acute and chronic infectious processes including Helicobacter pylori, Clostridium difficile, necrotizing enterocolitis, ventilator-associated pneumonia, vancomycin-resistant enterococci, and nonalcoholic fatty liver disease. It is inaccurate to generalize findings observed in a single probiotic species to all probiotics. This reasoning is due to the variability of colonizing abilities of native intestinal floras, probiotic or otherwise, secondary to different combinations, doses, and duration of treatments. Given these limitations, multiple animal and human studies have shown anti-inflammatory and selective antimicrobial effects of specific probiotics. Some studies suggest a role for probiotics as supplemental treatment, in combination with antibiotics, for the aforementioned disease processes. It is apparent from this review that the efficacy of probiotics is widely variable and multifaceted. More focused clinical and basic science research is necessary to better understand the treatment potential of various probiotics.


Probiotics Treatment Anti-inflammatory Antimicrobial 



No potential conflicts of interest relevant to this article were reported.


  1. 1.
    Fuller R. Probiotics in human medicine. Ann Med. 1990;22:37–41.CrossRefGoogle Scholar
  2. 2.
    Loprinzi CL, Levitt R, Barton DL, et al. Evaluation of shark cartilage in patients with advanced cancer: a north central cancer treatment group trial. Cancer. 2005;104(1):176–82.PubMedCrossRefGoogle Scholar
  3. 3.
    Bassler W. Civ. no. 99–5782 (WGB). US District Court for the District of New Jersey. 2004.Google Scholar
  4. 4.
    Suerbaum S, Michetti P. Helicobacter pylori infection. N Engl J Med. 2002;347(15):1175–86.PubMedCrossRefGoogle Scholar
  5. 5.
    Chey WD, Wong BC. Practice Parameters Committee of the American College of Gastroenterology. American college of gastroenterology guideline on the management of helicobacter pylori infection. Am J Gastroenterol. 2007;102(8):1808–25.PubMedCrossRefGoogle Scholar
  6. 6.
    Graham DY, Fischbach L. Helicobacter pylori treatment in the era of increasing antibiotic resistance. Gut. 2010;59(8):1143–53.PubMedCrossRefGoogle Scholar
  7. 7.
    Michetti P, Dorta G, Wiesel PH, et al. Effect of whey-based culture supernatant of lactobacillus acidophilus (johnsonii) La1 on helicobacter pylori infection in humans. Digestion. 1999;60(3):203–9.PubMedCrossRefGoogle Scholar
  8. 8.
    Mukai T, Tomoko A, Sato E, et al. Inhibition of binding of heliobacter pylori to the glycolipid receptors by probiotic lactobacillus reuteri. Immunol Med Microbiol. 2001;32:105–10.CrossRefGoogle Scholar
  9. 9.
    Lorca GL, Wadstrom T, Valdez GF, Ljungh A. Lactobacillus acidophilus autolysins inhibit helicobacter pylori in vitro. Curr Microbiol. 2001;42(1):39–44.PubMedCrossRefGoogle Scholar
  10. 10.
    Collado MC, Gonzalez A, Gonzalez R, Hernandez M, Ferrus MA, Sanz Y. Antimicrobial peptides are among the antagonistic metabolites produced by bifidobacterium against helicobacter pylori. Int J Antimicrob Agents. 2005;25(5):385–91.PubMedCrossRefGoogle Scholar
  11. 11.
    Tong JL, Ran ZH, Shen J, Zhang CX, Xiao SD. Meta-analysis: the effect of supplementation with probiotics on eradication rates and adverse events during helicobacter pylori eradication therapy. Aliment Pharmacol Ther. 2007;25(2):155–68.PubMedCrossRefGoogle Scholar
  12. 12.
    Szajewska H, Horvath A, Piwowarczyk A. Meta-analysis: the effects of saccharomyces boulardii supplementation on helicobacter pylori eradication rates and side effects during treatment. Aliment Pharmacol Ther. 2010;32(9):1069–79.PubMedCrossRefGoogle Scholar
  13. 13.
    Cindoruk M, Erkan G, Karakan T, Dursun A, Unal S. Efficacy and safety of saccharomyces boulardii in the 14-day triple anti-helicobacter pylori therapy: a prospective randomized placebo-controlled double-blind study. Helicobacter. 2007;12(4):309–16.PubMedCrossRefGoogle Scholar
  14. 14.
    Cremonini F, Di Caro S, Covino M, et al. Effect of different probiotic preparations on anti-helicobacter pylori therapy-related side effects: a parallel group, triple blind, placebo-controlled study. Am J Gastroenterol. 2002;97(11):2744–9.PubMedCrossRefGoogle Scholar
  15. 15.
    Duman DG, Bor S, Ozutemiz O, et al. Efficacy and safety of saccharomyces boulardii in prevention of antibiotic-associated diarrhoea due to helicobacterpylori eradication. Eur J Gastroenterol Hepatol. 2005;17(12):1357–61.PubMedCrossRefGoogle Scholar
  16. 16.
    Hurduc V, Plesca D, Dragomir D, Sajin M, Vandenplas Y. A randomized, open trial evaluating the effect of saccharomyces boulardii on the eradication rate of helicobacter pylori infection in children. Acta Paediatr. 2009;98(1):127–31.PubMedCrossRefGoogle Scholar
  17. 17.
    Song MJ, Park DI, Park JH, et al. The effect of probiotics and mucoprotective agents on PPI-based triple therapy for eradication of helicobacter pylori. Helicobacter. 2010;15(3):206–13.PubMedCrossRefGoogle Scholar
  18. 18.
    Kelesidis T, Pothoulakis C. Efficacy and safety of the probiotic saccharomyces boulardii for the prevention and therapy of gastrointestinal disorders. Therap Adv Gastroenterol. 2012;5(2):111–25.PubMedCrossRefGoogle Scholar
  19. 19.
    Safdar N, Maki DG. The commonality of risk factors for nosocomial colonization and infection with antimicrobial-resistant staphylococcus aureus, enterococcus, gram-negative bacilli, clostridium difficile, and candida. Ann Intern Med. 2002;136(11):834–44.PubMedGoogle Scholar
  20. 20.
    Drekonja DM, Butler M, MacDonald R, et al. Comparative effectiveness of clostridium difficile treatments: a systematic review. Ann Intern Med. 2011;155(12):839–47.PubMedGoogle Scholar
  21. 21.
    McFarland LV, Surawicz CM, Greenberg RN, et al. A randomized placebo-controlled trial of saccharomyces boulardii in combination with standard antibiotics for clostridium difficile disease. JAMA. 1994;271(24):1913–8.PubMedCrossRefGoogle Scholar
  22. 22.
    Surawicz C, McFarland L, Greenberg R. The search for a better treatment for recurrent clostridium difficile disease: Use of high-dose vancomycin combine with saccharomyces boulardii. Clin Infect Dis. 2000;31:1012–1017.Google Scholar
  23. 23.
    Lawrence SJ, Korzenik JR, Mundy LM. Probiotics for recurrent clostridium difficile disease. J Med Microbiol. 2005;54(Pt 9):905–6.PubMedCrossRefGoogle Scholar
  24. 24.
    McFarland LV. Meta-analysis of probiotics for the prevention of antibiotic associated diarrhea and the treatment of clostridium difficile disease. Am J Gastroenterol. 2006;101(4):812–22.PubMedCrossRefGoogle Scholar
  25. 25.
    Hickson M, D'Souza AL, Muthu N, et al. Use of probiotic lactobacillus preparation to prevent diarrhoea associated with antibiotics: randomised double blind placebo controlled trial. BMJ. 2007;335(7610):80.PubMedCrossRefGoogle Scholar
  26. 26.
    Pillai A, Nelson R. Probiotics for treatment of clostridium difficile-associated colitis in adults. Cochrane Database Syst Rev. 2008;(1)(1):CD004611.Google Scholar
  27. 27.
    Thilo E, Rosenberg A. The newborn infant. Current Diagnosis & Treatment (20th Edition): Pediatrics. 2011.Google Scholar
  28. 28.
    Frost BL, Caplan MS. Probiotics and prevention of neonatal necrotizing enterocolitis. Curr Opin Pediatr. 2011;23(2):151–5.PubMedCrossRefGoogle Scholar
  29. 29.
    Bin-Nun A, Bromiker R, Wilschanski M, et al. Oral probiotics prevent necrotizing enterocolitis in very low birth weight neonates. J Pediatr. 2005;147(2):192–6.PubMedCrossRefGoogle Scholar
  30. 30.
    Lin HC, Hsu CH, Chen HL, et al. Oral probiotics prevent necrotizing enterocolitis in very low birth weight preterm infants: a multicenter, randomized, controlled trial. Pediatrics. 2008;122(4):693–700.PubMedCrossRefGoogle Scholar
  31. 31.
    Deshpande G, Rao S, Patole S, Bulsara M. Updated meta-analysis of probiotics for preventing necrotizing enterocolitis in preterm neonates. Pediatrics. 2010;125(5):921–30.PubMedCrossRefGoogle Scholar
  32. 32.
    Alfaleh K, Anabrees J, Bassler D, Al-Kharfi T. Probiotics for prevention of necrotizing enterocolitis in preterm infants. Cochrane Database Syst Rev. 2011;(3)(3):CD005496.Google Scholar
  33. 33.
    Morrow LE, Kollef MH, Casale TB. Probiotic prophylaxis of ventilator-associated pneumonia: a blinded, randomized, controlled trial. Am J Respir Crit Care Med. 2010;182(8):1058–64.PubMedCrossRefGoogle Scholar
  34. 34.
    Sachdev G, Napolitano LM. Postoperative pulmonary complications: Pneumonia and acute respiratory failure. Surg Clin North Am. 2012;92(2):321–44, ix.Google Scholar
  35. 35.
    Napolitano LM. Perspectives in surgical infections: what does the future hold? Surg Infect (Larchmt). 2010;11(2):111–23.CrossRefGoogle Scholar
  36. 36.
    Klarin B, Molin G, Jeppsson B, Larsson A. Use of the probiotic lactobacillus plantarum 299 to reduce pathogenic bacteria in the oropharynx of intubated patients: a randomised controlled open pilot study. Crit Care. 2008;12(6):R136.PubMedCrossRefGoogle Scholar
  37. 37.
    Siempos II, Ntaidou TK, Falagas ME. Impact of the administration of probiotics on the incidence of ventilator-associated pneumonia: a meta-analysis of randomized controlled trials. Crit Care Med. 2010;38(3):954–62.PubMedCrossRefGoogle Scholar
  38. 38.
    Schultz MJ, Haas LE. Antibiotics or probiotics as preventive measures against ventilator-associated pneumonia: a literature review. Crit Care. 2011;15(1):R18.PubMedCrossRefGoogle Scholar
  39. 39.
    Vidal M, Forestier C, Charbonnel N, Henard S, Rabaud C, Lesens O. Probiotics and intestinal colonization by vancomycin-resistant enterococci in mice and humans. J Clin Microbiol. 2010;48(7):2595–8.PubMedCrossRefGoogle Scholar
  40. 40.
    Kim AS. Using the good to beat out the bad: probiotics for eliminating vancomycin-resistant enterococci colonization. J Clin Gastroenterol. 2011;45(10):844–5.PubMedCrossRefGoogle Scholar
  41. 41.
    Mlynarczyk A, Szymanek-Majchrzak K, Kosykowska E, et al. The dominant sequence types of vancomycin-resistant enterococcus faecium among transplantation ward patients. Transplant Proc. 2011;43(8):3132–4.PubMedCrossRefGoogle Scholar
  42. 42.
    Manley KJ, Fraenkel MB, Mayall BC, Power DA. Probiotic treatment of vancomycin-resistant enterococci: a randomised controlled trial. Med J Aust. 2007;186(9):454–7.PubMedGoogle Scholar
  43. 43.
    Szachta P, Ignys I, Cichy W. An evaluation of the ability of the probiotic strain lactobacillus rhamnosus GG to eliminate the gastrointestinal carrier state of vancomycin-resistant enterococci in colonized children. J Clin Gastroenterol. 2011;45(10):872–7.PubMedCrossRefGoogle Scholar
  44. 44.
    Ioannou GN, Boyko EJ, Lee SP. The prevalence and predictors of elevated serum aminotransferase activity in the united states in 1999–2002. Am J Gastroenterol. 2006;101(1):76–82.PubMedCrossRefGoogle Scholar
  45. 45.
    Clark JM, Brancati FL, Diehl AM. Nonalcoholic fatty liver disease. Gastroenterology. 2002;122(6):1649–57.PubMedCrossRefGoogle Scholar
  46. 46.
    Li Z, Yang S, Lin H, et al. Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease. Hepatology. 2003;37(2):343–50.PubMedCrossRefGoogle Scholar
  47. 47.
    Cani PD, Delzenne NM. The role of the gut microbiota in energy metabolism and metabolic disease. Curr Pharm Des. 2009;15(13):1546–58.PubMedCrossRefGoogle Scholar
  48. 48.
    Loguercio C, Federico A, Tuccillo C, et al. Beneficial effects of a probiotic VSL#3 on parameters of liver dysfunction in chronic liver diseases. J Clin Gastroenterol. 2005;39(6):540–3.PubMedCrossRefGoogle Scholar
  49. 49.
    Lirussi F, Mastropasqua E, Orando S. No evidence to support or refute probiotics for patients with non-alcoholic fatty liver disease and/or steatohepatitis. Cochrane Database of Systematic Reviews. 2007;CD005165.Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  • John Heineman
    • 1
  • Sara Bubenik
    • 1
  • Stephen McClave
    • 2
  • Robert Martindale
    • 1
    Email author
  1. 1.Division of General SurgeryOregon Health & Science UniversityPortlandUSA
  2. 2.University of LouisvilleLouisvilleUSA

Personalised recommendations